Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: PAFOOFNICK who wrote (251)	12/27/2004 7:10:57 PM
From: Tadsamillionaire	Respond to of 278

ADVR Receives FDA Approval of Its IND for AVR118 Monday December 27, 9:00 am ET YONKERS, N.Y.--(BUSINESS WIRE)--Dec. 27, 2004--Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) announced today that the Company has received approval from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the systemic use of AVR118 in patients with advanced malignancies. "ADVR has achieved a major milestone in the development of AVR118," said Dr. Elma Hawkins, President and CEO of Advanced Viral Research Corp. "We are very excited to be advancing this important drug into Phase II clinical trials in the U.S." After review of ADVR's IND which was submitted at the end of November 2004, the FDA notified the Company that it may proceed with its Phase II, multi-center clinical trial in the U.S. The study will examine the safety, tolerability and efficacy of AVR118 in patients with advanced cancer who are suffering from symptoms of progressive disease. Successful completion of this trial will then provide the platform to conduct further studies in patients with other complications of cancer. ADVR's AVR118 is a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid complex, which, to date, has demonstrated a very favorable safety profile, appears to stimulate the pro-inflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Data presented at the American Society of Clinical Oncology's (ASCO) annual meeting in June, 2004, showed that AVR118 appears to have activity against fatigue, loss of appetite, and weight loss in patients with HIV. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. ADVR, based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. biz.yahoo.com